Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma-Reference-Cited by-同舟云学术

Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma

Published:2017-06-23 Issue:6 Volume:141 Page:1265-1276
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

You Rui¹²^ORCID,Sun Rui¹²,Hua Yi-Jun¹²,Li Chao-Feng²³,Li Ji-Bin²⁴,Zou Xiong¹²,Yang Qi¹²,Liu You-Ping¹²,Zhang Yi-Nuan¹²,Yu Tao¹²,Cao Jing-Yu¹²,Zhang Meng-Xia¹²,Jiang Rou¹²,Mo Hao-Yuan¹²,Guo Ling¹²,Cao Ka-Jia¹²,Lin Ai-Hua⁵,Qian Chao-Nan¹²,Sun Ying¹⁶^ORCID,Ma Jun¹⁶,Chen Ming-Yuan¹²

Affiliation:

1. Department of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; 651 Dongfeng East Road Guangzhou 510060 People's Republic of China

2. Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou 510060 People's Republic of China

3. Department of Information Technology; Sun Yat-sen University Cancer Center; 651 Dongfeng East Road Guangzhou 510060 People's Republic of China

4. Department of Clinical Research; Sun Yat-sen University Cancer Center; 651 Dongfeng East Road Guangzhou 510060 People's Republic of China

5. Department of Medical Statistics and Epidemiology, School of Public Health; Sun Yat-sen University; 74 Zhongshan Second Road Guangzhou 510080 People's Republic of China

6. Department of Radiation Oncology; Sun Yat-sen University Cancer Center; 651 Dongfeng East Road Guangzhou 510060 People's Republic of China

Funder

Guangdong Provincial Natural Science Foundation in China

Program of Sun Yat-Sen University for Clinical Research 5010 Program

Program for New Century Excellent Talents in University

Major Project of Sun Yat-Sen University for the New Cross Subject and Special Support Program for High-level Talents in Sun Yat-Sen University Cancer Center (to M.Y.C.)

National Key Research and Development Program of China

Guangdong Public Welfare Research and Capacity Building Projects

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. The prevalence and prevention of nasopharyngeal carcinoma in China;Cao;Chin J Cancer,2011

2. National Comprehensive Cancer Network NCCN Guidelines: Head and neck cancers; Version 2.2013 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

3. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial;Chen;J Natl Cancer Inst,2011

4. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review;Trotti;Radiother Oncol,2003

5. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor;Ciardiello;Clin Cancer Res,2001

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The addition of nimotuzumab during concurrent chemoradiotherapy improved survival outcomes in locally advanced nasopharyngeal carcinoma patients with optimal response to induction chemotherapy;BMC Cancer;2024-08-02

2. Toripalimab plus cetuximab combined with radiotherapy in a locally advanced platinum-based chemotherapy-insensitive nasopharyngeal carcinoma patient: a case report;Frontiers in Oncology;2024-05-10

3. International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors;International Forum of Allergy & Rhinology;2024-01-02

4. Concurrent chemoradiotherapy plus anlotinib vs. concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: An interim analysis of a multicenter randomized controlled trial;ONCOL LETT;2023

5. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma;Holistic Integrative Oncology;2023-07-24